Skip to main content
Back

Greater China Equities: Driving the next leg of innovation 

24 December 2025

Kai Kong Chay, Senior Portfolio Manager, Greater China Equities

Wenlin Li, Senior Portfolio Manager, Greater China Equities

Ben Yu, Head of Equities, Taiwan Region

Greater China equity markets registered a strong equity rally in 2025 to date, driven by technology breakthroughs, demand for localisation, go-global demand, and upward earnings growth revisions. We reiterate a positive view on Greater China equity markets going into 2026 as we believe Mainland and Taiwan are well-positioned to drive high-quality growth to the next level.

Summary:

  1. We reiterate a positive view on Greater China equity markets going into 2026, supported by attractive valuations and resilient fund flows.
  2. We believe there are various investment opportunities for Mainland, notably in technology, industrials, renewable energy, healthcare, and new/niche/experienced consumption.
  3. For the Taiwan region, we expect further corporate earnings expansion in 2026, with structural growth opportunities in foundries, outsourced semiconductor assembly and test (OSAT) supply chain, thermal cooling solutions and power supply solutions.

 

Download the full version

 

  • Q&A: US equities outlook

    Michael J. Mattioli, Portfolio Manager, share his current view on US equities market, where geopolitical uncertainty and AI-driven change coexist with compelling opportunities.

    Read more
  • Navigating the global fixed-income landscape amid change: Question & Answer

    Bradley L. Lutz, Senior Portfolio Manager, and Jeffrey N. Given, Head of Developed-Market Fixed Income, share their views on global fixed income amid geopolitical risk, divergent central‑bank policies, elevated yields, currency management, and selective opportunities in a volatile market environment.

    Read more
  • 2026 Global healthcare equities outlook: Innovation supports healthcare’s long term case

    Global healthcare equities showed resilience amid 2025 volatility. The defensive characteristics, coupled with remarkable therapeutic innovations in the biopharmaceutical, MedTech, and tools sub-segments of this sector, will continue to be rewarded with capital appreciation over a full market cycle. Current valuations relative to the broader market make for an attractive entry point today, and periods like this tend to lead to outperformance for healthcare stocks over the long term.

    Read more
See all
  • Q&A: US equities outlook

    Michael J. Mattioli, Portfolio Manager, share his current view on US equities market, where geopolitical uncertainty and AI-driven change coexist with compelling opportunities.

    read more
  • Navigating the global fixed-income landscape amid change: Question & Answer

    Bradley L. Lutz, Senior Portfolio Manager, and Jeffrey N. Given, Head of Developed-Market Fixed Income, share their views on global fixed income amid geopolitical risk, divergent central‑bank policies, elevated yields, currency management, and selective opportunities in a volatile market environment.

    read more
  • 2026 Global healthcare equities outlook: Innovation supports healthcare’s long term case

    Global healthcare equities showed resilience amid 2025 volatility. The defensive characteristics, coupled with remarkable therapeutic innovations in the biopharmaceutical, MedTech, and tools sub-segments of this sector, will continue to be rewarded with capital appreciation over a full market cycle. Current valuations relative to the broader market make for an attractive entry point today, and periods like this tend to lead to outperformance for healthcare stocks over the long term.

    read more
see all